Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-Day Oral Contraceptive DR-1021
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Duramed Investigational Site
-
Mobile, Alabama, United States, 36608
- Duramed Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- Duramed Investigational Site
-
Phoenix, Arizona, United States, 85031
- Duramed Investigational Site
-
-
California
-
Carmichael, California, United States, 95608
- Duramed Investigational Site
-
Irvine, California, United States, 92618
- Duramed Investigational Site
-
San Diego, California, United States, 92108
- Duramed Investigational Site
-
San Diego, California, United States, 92123
- Duramed Investigational Site
-
San Ramon, California, United States, 94583
- Duramed Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- Duramed Investigational Site
-
Lakewood, Colorado, United States, 80228
- Duramed Investigational Site
-
-
Delaware
-
Wilmington, Delaware, United States, 19805
- Duramed Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20006
- Duramed Investigational Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Duramed Investigational Site
-
Boynton Beach, Florida, United States, 33437
- Duramed Investigational Site
-
Brooksville, Florida, United States, 33613
- Duramed Investigational Site
-
Clearwater, Florida, United States, 33761
- Duramed Investigational Site
-
Coral Gables, Florida, United States, 33134
- Duramed Investigational Site
-
Fort Meyers, Florida, United States, 33918
- Duramed Investigational Site
-
Leesburg, Florida, United States, 34748
- Duramed Investigational Site
-
Longwood, Florida, United States, 32779
- Duramed Investigational Site
-
Miami, Florida, United States, 33173
- Duramed Investigational Site
-
Pinellas Park, Florida, United States, 33781
- Duramed Investigational Site
-
Sarasota, Florida, United States, 34239
- Duramed Investigational Site
-
St. Petersburg, Florida, United States, 33702
- Duramed Investigational Site
-
St. Petersburg, Florida, United States, 33709
- Duramed Investigational Site
-
Tampa, Florida, United States, 33613
- Duramed Investigational Site
-
West Palm Beach, Florida, United States, 33409
- Duramed Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Duramed Investigational Site
-
Atlanta, Georgia, United States, 30328
- Duramed Investigational Site
-
Decatur, Georgia, United States, 30034
- Duramed Investigational Site
-
Roswell, Georgia, United States, 30075
- Duramed Investigational Site
-
-
Idaho
-
Boise, Idaho, United States, 83704
- Duramed Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Duramed Investigational Site
-
Chicago, Illinois, United States, 60612
- Duramed Investigational Site
-
Peoria, Illinois, United States, 61602
- Duramed Investigational Site
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66216
- Duramed Investigational Site
-
Topeka, Kansas, United States, 66614
- Duramed Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Duramed Investigational Site
-
Louisville, Kentucky, United States, 40291
- Duramed Investigational Site
-
Mt Sterling, Kentucky, United States, 40353
- Duramed Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Duramed Investigational Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Duramed Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- Duramed Investigational Site
-
-
New Jersey
-
Moorestown, New Jersey, United States, 08057
- Duramed Investigational Site
-
New Brunswick, New Jersey, United States, 08901
- Duramed Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Duramed Investigational Site
-
-
New York
-
Johnson City, New York, United States, 13790
- Duramed Investigational Site
-
Rochester, New York, United States, 14609
- Duramed Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
- Duramed Investigational Site
-
Raleigh, North Carolina, United States, 27612
- Duramed Investigational Site
-
Wilmington, North Carolina, United States, 28412
- Duramed Investigational Site
-
Winston-Salem, North Carolina, United States, 27103
- Duramed Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Duramed Investigational Site
-
Columbus, Ohio, United States, 43213
- Duramed Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Duramed Investigational Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Duramed Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19114
- Duramed Investigational Site
-
Reading, Pennsylvania, United States, 19606
- Duramed Investigational Site
-
-
Rhode Island
-
Cranston, Rhode Island, United States, 02920
- Duramed Investigational Site
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
- Duramed Investigational Site
-
Mt Pleasant, South Carolina, United States, 29464
- Duramed Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Duramed Investigational Site
-
Chattanooga, Tennessee, United States, 37404
- Duramed Investigational Site
-
Clarksville, Tennessee, United States, 37043
- Duramed Investigational Site
-
Germantown, Tennessee, United States, 38138
- Duramed Investigational Site
-
Knoxville, Tennessee, United States, 37920
- Duramed Investigational Site
-
Nashville, Tennessee, United States, 37203
- Duramed Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78759
- Duramed Investigational Site
-
Dallas, Texas, United States, 75234
- Duramed Investigational Site
-
Houston, Texas, United States, 77030
- Duramed Investigational Site
-
San Antonio, Texas, United States, 78229
- Duramed Investigational Site
-
Waco, Texas, United States, 76712
- Duramed Investigational Site
-
-
Utah
-
Magna, Utah, United States, 84044
- Duramed Investigational Site
-
Pleasant Grove, Utah, United States, 84062
- Duramed Investigational Site
-
Salt Lake City, Utah, United States, 84124
- Duramed Investigational Site
-
Sandy, Utah, United States, 84070
- Duramed Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22203
- Duramed Investigational Site
-
Newport News, Virginia, United States, 23602
- Duramed Investigational Site
-
Norfolk, Virginia, United States, 23507
- Duramed Investigational Site
-
Richmond, Virginia, United States, 23233
- Duramed Investigational Site
-
-
Washington
-
Lakewood, Washington, United States, 98499
- Duramed Investigational Site
-
Seattle, Washington, United States, 98105
- Duramed Investigational Site
-
Spokane, Washington, United States, 99207
- Duramed Investigational Site
-
Tacoma, Washington, United States, 98405
- Duramed Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Premenopausal
- Not pregnant or breastfeeding
- Sexually active at risk of pregnancy
Exclusion Criteria:
- Any contraindication to the use of oral contraceptives
- Pregnancy within the last 3 months
- Smoking > 10 cigarettes per day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
1 tablet daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluation of pregnancy rates
Time Frame: Duration of study
|
Duration of study
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events reported by patients and investigators
Time Frame: Duration of study
|
Duration of study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Duramed Medical Monitor, Duramed Research
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- DR-DSG-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.